|
Primary and secondary efficacy criteria: complete or partial abstinence during the 28 days preceding the 6-week visit (adopted from [17]) |
||
| Group\Statistical results |
Nicotinell® lozenge 1 mg |
Placebo |
|
|
||
| (n = 211) |
(n = 222) |
|
|
|
||
| Complete abstinence (%) |
48 (23%) |
32 (14%) |
| OR [95% CI] |
1.72 [1.05–2.80] |
|
| Statistical significance |
p = 0.03 |
|
| Complete or partial abstinence (%) |
68 (32%) |
39 (18%) |
| OR [95% CI] |
2.18 [1.40–3.41] |
|
| Statistical significance |
p = 0.001 |
|
|
Complete abstinence = subjects declaring not to smoke + exhaled-breath CO <10 ppm. Partial abstinence = subjects smoking ≤ 1 cigarette/day and ≤ 7 cigarettes/week + exhaled-breath CO <10 ppm. | ||
Dautzenberg et al. BMC Clinical Pharmacology 2007 7:11 doi:10.1186/1472-6904-7-11 |
||